The Kidney Health Australia reveals that healthcare costs pertaining to the existing as well as new cases of kidney disease will touch USD 12 billion by 2022.
Going forward, the Centers for Disease Control & Prevention says that close to 15% of Americans are expected to develop chronic kidney disease by 2021.
Reports also confirm that a whopping 96% of patients suffering from kidney damage are not even aware of about the condition, which should foster the growth potential of the chronic kidney disease drugs industry in the years ahead.
Alarming rise in cases of high blood pressure and diabetes is also bound to create favorable avenues for the global market.The chronic kidney disease industry also stands to profit from the burgeoning aging population, which is susceptible to various diseases including kidney and urinary disorders.
Canada along with the US house a huge patient pool suffering from chronic kidney and urinary disorders given the prevalence of sedentary lifestyles in these countries.
In addition, government funds for developing the healthcare infrastructure should favor the market in subsequent years.Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/5744 Market SegmentationThe chronic kidney disease industry has been segregated with respect to diagnosis, treatment, indication, and end-user.The diagnosis-based segments are urine test, blood test, kidney biopsy and imaging test.Treatment-wise, the market caters to dialysis, kidney transplant and drugs.The indications covered in the report are polycystic kidney disease, high blood pressure, Type 1 or Type 2 diabetes, and others.Major market end-user considered in the study are diagnostic centers, hospitals and clinics, and others.Regional AnalysisThe chronic kidney disease industry has been geographically divided into Europe, APAC/Asia Pacific, MEA/Middle East & Africa and the Americas.The American market for chronic kidney disease is in the lead, considering the expanding population of patients affected by kidney diseases and the extensive demand for kidney disease diagnostic tests.